Hutchmed (China) Limited American Depositary Shares (HCM)
HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript
HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript
3 HCM Stocks to Consider After January's Strong U.S. Jobs Report
These human capital management stocks are starting to make an argument for being in oversold territory following January's strong U.S. Jobs report.
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know
The consensus price target hints at a 55.9% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst
Edgewise Therapeutics, Inc. maintains a Buy rating, driven by favorable interim 12-week safety data for EDG-7500 in phase 2 CIRRUS-HCM and multiple 2026 catalysts. EDG-7500 demonstrated strong tolerability and no clinically meaningful LVEF reductions, potentially differentiating it from cardiac myosin inhibitors for HCM treatment. Key 2026 catalysts include phase 2 CIRRUS-HCM efficacy data in Q2 2026 and potential phase 3 initiation for EDG-7500 in Q4 2026, targeting both oHCM and nHCM patients.
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript
HUTCHMED (China) Limited ( HCM ) HUTCHMED (China) Limited Deutsche Bank ADR Virtual Investor Conference 2025 November 4, 2025 8:00 AM EST Company Participants David Ng - Head of Investor Relations & Capital Strategies Conference Call Participants Zafar Aziz - Deutsche Bank Aktiengesellschaft Presentation Zafar Aziz Deutsche Bank Aktiengesellschaft Hello, and Welcome to Deutsche Bank's Virtual Investor Conference, dbVIC. This is Zafar Aziz from the Deutsche Bank team.
HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
HUTCHMED (China) Limited ( HCM ) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update October 31, 2025 8:00 AM EDT Company Participants David Ng - Head of Investor Relations & Capital Strategies Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Conference Call Participants Alec Stranahan - BofA Securities, Research Division Khalil Fenina - Goldman Sachs Group, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Adam McCarter - Cavendish Securities plc, Research Division Presentation David Ng Head of Investor Relations & Capital Strategies Hello, everyone. Good evening and good morning.
HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Chig Fung Cheng - CFO & Executive Director David Ng - Head of Investor Relations & Capital Strategies George Yuan - Corporate Participant Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Conference Call Participants Chen Chen - UBS Investment Bank, Research Division Matthew Yan - Unidentified Company Paul Choi - Goldman Sachs Group, Inc., Research Division David Ng Hello, everyone. This is David Ng, Head of Investor Relations of HUTCHMED.
How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.5% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Paycom Software: Automating Payroll And HCM Solutions; Initiate With 'Buy'
I am initiating Paycom with a 'buy' rating and a $280 fair value, driven by strong automation-focused HCM solutions. Paycom's innovations like Beti and GONE automate payroll and time-off processes, supporting double-digit topline growth and high customer ROI. The company is expanding into mid-to-large enterprise markets, leveraging AI and automation to capture market share and drive 9% organic revenue growth.
Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestone
Shares in Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013) rose 10% in early trading on Tuesday after the biopharma company announced it had completed patient enrolment for a key phase II trial of its cancer drug savolitinib in China. The study is testing the treatment in people with gastric or gastroesophageal junction cancer whose tumours show MET gene amplification - a relatively rare but aggressive subtype.
3 Internet Delivery Services Stocks in Focus Amid Industry Challenges
Tariff war, inflationary pressure and still-high interest rates are major concerns for the Zacks Internet - Delivery Services industry. However, efforts to adopt consumer preferences and technological advancements are likely to help GDDY, QNST and ASUR navigate the headwinds.
